Navigation Links
Mylan Canada Receives Health Canada Approval for Generic Version of Crestor®
Date:3/15/2012

PITTSBURGH and TORONTO, March 15, 2012 /PRNewswire/ -- Mylan Pharmaceuticals ULC, the Canadian subsidiary of Mylan Inc. (NASDAQ: MYL), today received approval from Health Canada for Mylan-Rosuvastatin Calcium Tablets, 5mg, 10mg, 20mg and 40mg. Mylan-Rosuvastatin is the generic version of Astra Zeneca's Crestor® Tablets, which are used for the management of primary hypercholesterolaemia, mixed dyslipidaemia, and familial hypercholesterolaemia.  According to IMS Health, Rosuvastatin Calcium Tablets, 5mg, 10mg, 20mg and 40mg, had Canadian sales of approximately $742 million for the 12 months ending Dec. 31, 2011.

"We are very pleased to introduce Mylan-Rosuvastatin to the Canadian market," said Dick Guest, president of Mylan Canada. "According to the Canadian Heart and Stroke Foundation, 'about 40% of Canadians have high blood cholesterol.'[1] Not only does this introduction provide Canadians with access to our quality medicine, it does so at a substantially lower cost. The introduction of generic medicines like Mylan-Rosuvastatin helps to contribute to a sustainable health care system."

Currently, Mylan Canada has 42 product applications pending Health Canada approval representing $3.6 billion in annual sales, according to IMS Health.

In Canada, generic drugs cost consumers an average of 60% less than their brand name counterparts. 

Mylan-Rosuvastatin is contraindicated in patients who are hypersensitive to it and in patients with active liver disease.  Pregnant women or women wishing to become pregnant should not take Rosuvastatin, as well as patients taking cyclosporine.

About Mylan
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan in Canada, please visit www.mylan.ca. For more information about generic drugs, please visit www.ChoosingGenerics.ca.

[1] http://www.heartandstroke.com/site/c.ikIQLcMWJtE/b.3483991/k.34A8/Statistics.htm  


'/>"/>
SOURCE Mylan Pharmaceuticals ULC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
2. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
3. Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
4. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
5. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
6. Mylan Receives Approval for Generic Version of GoLytely(R)
7. Mylan Declares Quarterly Preferred Stock Dividend
8. Mylan Pre-Pays All Scheduled 2011 Term-Loan Borrowings
9. Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication
10. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
11. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... LONDON , March 28, 2017 ... report,"Evolving Pharmaceutical Marketing Strategies: Digital as a Key ... of the changing pharmaceutical marketing landscape in the ... adopts new technologies to provide medical advancements, it ... its marketing efforts, mostly relying on traditional channels ...
(Date:3/28/2017)... TORONTO , March 28, 2017 /PRNewswire/ ... full service medical device development firm, announced today that ... Toronto -based medical device industrial design and ... medtech companies throughout North America ... medical device talent spanning the design, engineering, regulatory, and ...
(Date:3/28/2017)... , March 28, 2017 Emosis SAS, ... new business entity, Emosis Ltd, headquartered in Tel Aviv ... novel assays complementing the mother company existing technology platform and test ... sales development of Emosis kits. ... This strategic move starts building Emosis international footprint. Emosis ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... HealthCareMandA.com will host an important webinar ... at 1:00 PM ET. A recording of the webinar will also be made available ... Home health and hospice companies are still popular targets for healthcare investors. This highly ...
(Date:3/29/2017)... Cranbury, NJ (PRWEB) , ... March 29, 2017 ... ... Annual School of Gastrointestinal Oncology™ (SOGO™), a specialized continuing medical education conference for ... April 29 at Intercontinental Time Square, New York. , The program will ...
(Date:3/28/2017)... Angeles, CA (PRWEB) , ... March 28, 2017 , ... ... call” asking the American public to take the Diabetes Risk Test to find out ... event, the Los Angeles World Airports will light up the evening sky by programming ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... in state legislatures and Congress to protect parental rights and civil liberties, and ... safety in America. , The demonstration coincides with a press conference taking place ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... the science and clinical practice of radiosurgery, announced today the publication of ... observational registry established to standardize data collection from patients treated with stereotactic ...
Breaking Medicine News(10 mins):